Diary - News
All news Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes
• Imeglimin Phase 2b trial in 299 Japanese patients achieved statistical significance for the primary and key secondary endpoints • Les rés
• Imeglimin Phase 3 program in Japan is anticipated to initiate in the fourth quarter of 2017
• The Japanese diabetes market is fast-growing and anticipated to reach approximately $6B by 2020
Lyon, France, May 4, 2017 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat metabolic diseases, including type 2 diabetes, announced today positive top line Phase 2b data results for Imeglimin for the treatment of type 2 diabetes in Japan.
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree